A Primer for Family Medicine and Primary Care: Focusing on Pompe Disease
Tracking # 20-686715
Free
There are no ratings for this course
Learn moreCourse overview
Recognizing Pompe disease, a progressive, debilitating and often fatal neuromuscular disease caused by a genetic deficiency or dysfunction of the lysosomal enzyme acid alpha-glucosidase (GAA), can be challenging, as its signs and symptoms are like those of other diseases and disorders. As a result, Pompe disease may not be readily considered during the clinical work up and significant diagnostic delays are common in many patients. During this activity, we shall review the importance of early diagnosis, how the disease can present at different ages through sample case vignettes, as well as discuss advances in the ongoing monitoring and management of these patients. Early recognition is critical for improved outcomes since the disease continues to progress relentlessly, with many patients going undiagnosed for years, with debilitating and often life-threatening impact.
Subject areas
This course counts toward the state boards and subject areas below.
Bahamas Medical Council
Medical Practitioner
Specialty Medical Practitioner
New Mexico Board of Nursing
Registered Nurse
State Medical Board of Ohio
Doctor of Medicine
Doctor of Osteopathic Medicine
West Virginia Board of Registered Nurses
Advanced Practice Registered Nurse
Registered Nurse
Disclosure statements
Presenter: Priya Kishnani, MD has indicated that she has received research grant support from Sanofi Genzyme, Valerion Therapeutics, and Amicus Therapeutics; consulting fees and honoraria from Sanofi Genzyme, Amicus Therapeutics, Vertex, and Asklepios Biopharmaceutical (AskBio), and is a member of the Pompe and Gaucher disease advisory board for Sanofi Genzyme, Amicus Therapeutics, and Baebies. She also has equity in AskBio Therapeutics.
Peer reviewer and EXCEL staff have no relevant financial information to disclose.